<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664465</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC20.0274</org_study_id>
    <nct_id>NCT04664465</nct_id>
  </id_info>
  <brief_title>PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS</brief_title>
  <acronym>PRODIGIOUS</acronym>
  <official_title>PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, there is no available tool that allows, at individual level, determination of the&#xD;
      probability to develop clinically relevant complications of prolonged glucocorticoid therapy.&#xD;
      In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy,&#xD;
      such tool could be useful to adapt first-line treatment decisions (in daily practice and in&#xD;
      future clinical trials). The main objective of the study is to identify routine clinical,&#xD;
      biological and DXA baseline characteristics predictive of the occurrence of clinically&#xD;
      relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive&#xD;
      score.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically relevant complication of glucocorticoid therapy</measure>
    <time_frame>1 year</time_frame>
    <description>The occurrence of one or more clinically relevant complication of glucocorticoid therapy during the first year of treatment, according to the Glucocorticoid Toxicity Index (items and specific list).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed through SF-36</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Inflammatory Rheumatism</condition>
  <condition>Polymyalgia Rheumatica</condition>
  <condition>Giant Cell Arteritis</condition>
  <condition>Idiopathic Inflammatory Myopathies</condition>
  <condition>ANCA Associated Vasculitis</condition>
  <condition>Systemic Autoimmune Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients usually treated with prolonged glucocorticoid therapy in the field of&#xD;
        rheumatology.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &gt; 1 year.&#xD;
&#xD;
          -  Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day for&#xD;
             the treatment of an inflammatory rheumatic disease.&#xD;
&#xD;
          -  Initial treatment or relapse.&#xD;
&#xD;
          -  Previsional treatment duration &gt; 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to consent.&#xD;
&#xD;
          -  Previous corticosteroid therapy in the last 3 months at a significant dosage (&gt; 5 mg&#xD;
             per day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dewi GUELLEC</last_name>
    <phone>02-98-34-72-64</phone>
    <email>dewi.guellec@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Béatrice BOUVARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dewi GUELLEC</last_name>
      <email>dewi.guellec@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Grégoire CORMIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle DERNIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29672</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine LE HENAFF-BOURHIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benoit LE GOFF</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric LESPASAILLES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>&lt;CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabeth GERVAIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHIC Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Carole DUQUENNE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe GOUPILLE</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning three years and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

